Pneumococcal infections - Pipeline Insight, 2024

This Pneumococcal infections - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Pneumococcal infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pneumococcal infections Understanding

Pneumococcal infections: Overview

Pneumococcal infections: Overview Pneumococcal infections are caused by Streptococcus pneumoniae, a gram-positive, catalase-negative organism commonly referred to as pneumococcus. The bacteria spread through contact with people who are ill or by healthy people who carry the bacteria in the back of their nose. Pneumococcal infections can be mild or severe. Symptoms of pneumococcal infections vary depending on the site of the infection. Most pneumococcal infections occur in the Lungs (pneumonia), Middle ear (otitis media, which is common among children), Sinuses (sinusitis) Pneumococcal infections usually fall into one of two categories: non-invasive pneumococcal infections - these occur outside the major organs or the blood and tend to be less serious and invasive pneumococcal infections - these occur inside a major organ or the blood and tend to be more serious. People with a weakened immune system are most at risk of catching a pneumococcal infection. Diagnosis is based on the physical exam and medical history. Treatment is with antibiotics and vaccines that can prevent pneumococcal infections.

Pneumococcal infections - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pneumococcal infections pipeline landscape is provided which includes the disease overview and Pneumococcal infections treatment guidelines. The assessment part of the report embraces, in depth Pneumococcal infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pneumococcal infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Pneumococcal infections R&D. The therapies under development are focused on novel approaches to treat/improve Pneumococcal infections.
• In February 2022, Affinivax and Astellas Pharma announced that they have entered into an agreement whereby Affinivax has reacquired the exclusive worldwide rights to ASP3772, a novel vaccine candidate targeting Streptococcus pneumoniae.
• This segment of the Pneumococcal infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pneumococcal infections Drugs
ASP3772: AffinivaxASP3772 is designed to elicit both B-cell (antibody) and T-cell immune protection against Streptococcus pneumoniae. ASP3772 includes 24 pneumococcal polysaccharides, as well as two conserved pneumococcal proteins. The results from the Phase II clinical trial demonstrated that ASP3772 was well tolerated. ASP3772 also exhibited an antibody response to each of the 24 polysaccharides, as well as an additional antibody response to the conserved pneumococcal proteins. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for ASP3772 for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes included in ASP3772 in adults aged 50 years and older. The FDA decision is informed by the results of the Phase 2 clinical data. The FDA’s Breakthrough Therapy process is designed to expedite the development and review of drugs that are intended to treat a serious or life-threatening condition.

Pneumococcal infections: Therapeutic Assessment

This segment of the report provides insights about the Pneumococcal infections drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pneumococcal infections

There are approx. 15+ key companies which are developing the therapies for Pneumococcal infections. The companies which have their Pneumococcal infections drug candidates in the most advanced stage, i.e. Phase II include Affinivax.

Phases

This report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Pneumococcal infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pneumococcal infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pneumococcal infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pneumococcal infections drugs.

Pneumococcal infections Report Insights

• Pneumococcal infections Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pneumococcal infections Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pneumococcal infections drugs?
• How many Pneumococcal infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pneumococcal infections?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pneumococcal infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pneumococcal infections and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• GlaxoSmithKline
• Gangagen
• CanSino Biologics Inc.
• Pfizer
• Merck Sharp & Dohme
• EuBiologics
• Beijing Zhifei Lvzhu Biopharmaceutical
• SK Chemicals Co., Ltd.
• LG Life Sciences
• Astellas Pharma
• Affinivax
• ImmunoBiology
• Panacea Biotech
• SutroVax
• Vaxcyte

Key Products

Research programme: Pneumococcal infections therapeutics- Pneumococcal vaccine

• PF 06842433
• V 116
• EuPCV15
• V 114
• ASP3772
• 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
• Pneumococcal vaccine conjugate 10-valent
• VAX 24
• VAX XP

This product will be delivered within 1-3 business days.